Separately, Independent Research set a €10.80 ($12.56) target price on MediGene and gave the company a neutral rating in a report on Wednesday, November 28th.
MDG1 opened at €10.01 ($11.64) on Monday. MediGene has a 12-month low of €8.53 ($9.92) and a 12-month high of €19.27 ($22.41).
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase.
Featured Story: Capital gains and your 401(k) or IRA
Receive News & Ratings for MediGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediGene and related companies with MarketBeat.com's FREE daily email newsletter.